Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03215693 | X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib | unknown | Phase 2 | 152 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05991895 | Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer | unknown | — | 5,000 | Jinming YuOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05102214 | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 150 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05978401 | Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 152 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05975944 | Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 49 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05974007 | Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC(NeoR-World) | unknown | — | 1,500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05739006 | Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | unknown | Phase 1 | 131 | BiocadINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05962021 | Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation | unknown | Phase 2 | 126 | Peking University People's HospitalOTHER | 0 | Aug 1, 2023 | clinicaltrials |
| NCT05648955 | Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment(ALLIES) | unknown | Early Phase 1 | 118 | Nutricia ResearchINDUSTRY | 1 | Jul 28, 2023 | clinicaltrials |
| NCT05965102 | Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer | unknown | Phase 1 | 31 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Jul 28, 2023 | clinicaltrials |
| NCT05794711 | Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015) | unknown | — | 1,063 | Fudan UniversityOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05794724 | Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016) | unknown | — | 1,063 | Fudan UniversityOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05094882 | Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010) | unknown | — | 500 | Fudan UniversityOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05731518 | SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | unknown | Phase 1 / Phase 2 | 67 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05932264 | Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05127590 | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | unknown | Phase 1 / Phase 2 | 50 | Ribon Therapeutics, Inc.INDUSTRY | 4 | Jul 3, 2023 | clinicaltrials |
| NCT05925738 | Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer | unknown | — | 1,500 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05925751 | Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer | unknown | — | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05921474 | Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors(SABR-DETECT) | unknown | — | 100 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05919641 | LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT(LIVELUNG) | unknown | — | 130 | Odense University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05910034 | Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC | unknown | Phase 2 | 132 | Fudan UniversityOTHER | 0 | Jun 18, 2023 | clinicaltrials |
| NCT05489731 | VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer(VIC-1911) | unknown | Phase 1 | 72 | Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.OTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04726358 | ProCaLung: Project on Cancer of the Lung(ProCaLung) | unknown | — | 1,000 | Jules Bordet InstituteOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT05900219 | Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study | unknown | Phase 2 | 75 | Shanghai Kechow Pharma, Inc.INDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05896059 | A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC | unknown | Phase 2 | 21 | Zhejiang Cancer HospitalOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05527808 | A Single-arm Exploratory Study of Neoadjuvant Therapy | unknown | N/A | 28 | Jun LiuOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05780307 | IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors | unknown | Phase 1 | 48 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT03568097 | Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer(PAVE) | unknown | Phase 2 | 55 | Hellenic Cooperative Oncology GroupOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05498389 | EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | unknown | Phase 1 / Phase 2 | 115 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Jun 1, 2023 | clinicaltrials |
| NCT03797391 | A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 186 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | May 31, 2023 | clinicaltrials |
| NCT05306652 | Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment(EXcellenT) | unknown | N/A | 40 | AUSL Romagna RiminiOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05882630 | Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 1 | May 31, 2023 | clinicaltrials |
| NCT04580498 | A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC | unknown | Phase 2 | 107 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT05865730 | A Study of Oncobax®-AK in Patients With Advanced Solid Tumors | unknown | Phase 2 | 122 | EverImmuneINDUSTRY | 2 | May 19, 2023 | clinicaltrials |
| NCT05859373 | To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer. | unknown | Phase 1 / Phase 2 | 78 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT04202809 | Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.(ESPADURVA) | unknown | Phase 2 | 90 | University Hospital, EssenOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05157776 | A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations | unknown | Phase 3 | 72 | Tongji UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05847764 | Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | unknown | Phase 2 | 95 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT03217669 | Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy | unknown | Phase 1 | 15 | Chao HuangOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04542369 | Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT03827070 | Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma(DPTA) | unknown | Phase 1 | 12 | Center Trials & Treatment EuropeNETWORK | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05819905 | Radiomics for prEdiction of lunG cAncer biologY | unknown | — | 600 | Poitiers University HospitalOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05815472 | Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)(APALITT) | unknown | N/A | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05813522 | Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT03908671 | Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer | unknown | N/A | 24 | Stemirna TherapeuticsINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05810350 | Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles | unknown | Phase 2 | 40 | Three Gorges Hospital of Chongqing UniversityOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 16, 2023source: clinicaltrials